Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | TERT | O14746 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.39 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.39 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7167530 | 0.88 | MAPT (0.47) | MAPTKMT2AMEN1ALDH1A1CYP1A2 | |
| SCHEMBL7001048 | 0.86 | MAPT (0.47) | MAPTKMT2AMEN1ALDH1A1CYP1A2 | |
| SCHEMBL7000027 | 0.85 | MEN1 (0.65) | MAPTKMT2AMEN1ALDH1A1CYP1A2 | |
| SCHEMBL7492463 | 0.82 | MAPT (0.69) | MAPTKMT2AMEN1ALDH1A1CYP1A2 | |
| SCHEMBL7491310 | 0.81 | MAPT (0.42) | MAPTKMT2AMEN1ALDH1A1CYP1A2 | |
| SCHEMBL7498649 | 0.81 | MAPT (0.45) | MAPTKMT2AMEN1ALDH1A1CYP1A2 | |
| SCHEMBL7226781 | 0.80 | MAPT (0.44) | MAPTKMT2AMEN1ALDH1A1CYP1A2 | |
| SCHEMBL7163609 | 0.79 | MAPT (0.47) | MAPTKMT2AMEN1ALDH1A1CYP1A2 | |
| SCHEMBL7225773 | 0.79 | MAPT (0.50) | MAPTKMT2AMEN1ALDH1A1CYP1A2 | |
| SCHEMBL7236400 | 0.79 | MAPT (0.47) | MAPTKMT2AMEN1ALDH1A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1003749-B1 | 8-SUBSTITUTED-9H-1,3-DIOXOLO/4,5-h/2,3/BENZODIAZEPINE DERIVATES, AS AMPA/KAINATERECEPTOR INHIBITORS | EGYT GYOGYSZERVEGYESZETI GYAR (HU) | 2003-10-22 | — | — | EP | disclosed |
| US-6600036-B2 | Treating diseases of the central nervous system. | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-07-29 | — | — | US | disclosed |
| US-6562810-B1 | Competitive AMPA/kainite antagonist properties making them useful in the treatment of diseases where inhibition of the AMPA/kainite receptors may a favorable effect | EGIS GYOGYSZERGYAR RT. (HU) | 2003-05-13 | — | — | US | disclosed |
| US-20020052364-A1 | Condensed 2,3-benzodiazepine derivatives and their use as AMPA-receptor inhibitors | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2002-05-02 | — | — | US | disclosed |
| EP-0888356-B1 | CONDENSED 2,3-BENZODIAZEPINE DERIVATIVES AND THEIR USE AS AMPA-RECEPTOR INHIBITORS | SCHERING AG (DE) | 2002-03-20 | — | — | EP | disclosed |
| US-6323197-B1 | NON-COMPETITIVE INHIBITING OF THE AMPA RECEPTORS, THESE COMPOUNDS CAN BE USED AS MEDICAMENTS FOR TREATMENT OF THE CENTRAL NERVOUS SYSTEM | SCHERING AKTIENGESELLSCHAFT (DE) | 2001-11-27 | — | — | US | disclosed |
| EP-0888356-A1 | CONDENSED 2,3-BENZODIAZEPINE DERIVATIVES AND THEIR USE AS AMPA-RECEPTOR INHIBITORS | SCHERING AKTIENGESELLSCHAFT (DE) | 1999-01-07 | — | — | EP | disclosed |
| WO-1997028163-A1 | CONDENSED 2,3-BENZODIAZEPINE DERIVATIVES AND THEIR USE AS AMPA-RECEPTOR INHIBITORS | SCHERING AKTIENGESELLSCHAFT (DE) | 1997-08-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020052364-A1 | Condensed 2,3-benzodiazepine derivatives and their use as AMPA-receptor inhibitors | GABRE, GABRA2, GABRB2 | MAPT 999/4885KMT2A 1184/4885MEN1 4186/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.